neurochondrin

12/01/2019 - "Neurochondrin Antibody Serum Positivity in Three Cases of Autoimmune Cerebellar Ataxia."
01/01/2023 - "Cerebellar ataxia associated with anti-neurochondrin antibodies has only been described in 19 cases; however, the number of unrecognized PACAs may be higher. "
01/01/2023 - "Anti-neurochondrin antibody as a biomarker in primary autoimmune cerebellar ataxia-a case report and review of the literature."
01/01/2021 - "Nonparaneoplastic cerebellar ataxia occurs with Septin-5 and neurochondrin antibodies. "
01/01/2017 - "No such neurochondrin reactivity was found in control cohorts of various neural autoantibody-associated neurologic syndromes, relapsing-remitting multiple sclerosis, cerebellar type of multiple system atrophy, hereditary cerebellar ataxias, other neurologic disorders, or healthy donors. "

12/01/2019 - "To report three cases of autoimmune ataxia patients with positive neurochondrin (NCDN) antibodies. "
01/15/2022 - "Neurochondrin immunoglobulin G - Associated myelopathy - Ataxia syndrome."
01/01/2021 - "Recurrent Ataxia and Dystonia with Anti-Neurochondrin Autoantibodies."

01/01/2018 - "In addition, we measured the group 1 mGluR endogenous regulators, neurochondrin and Homer1b/c, which have recently been implicated in the pathophysiology of schizophrenia. "
07/01/2015 - "We assessed mGluR5 mRNA and protein levels in the dorsolateral prefrontal cortex (DLPFC) using a large cohort of schizophrenia and control subjects (n = 37/group), and additionally measured protein levels of recently discovered mGluR5 endogenous regulators, Norbin (neurochondrin), Tamalin (GRASP-1), and Preso1 (FRMPD4), which regulate mGluR5 localization, internalization and signaling. "

06/01/2020 - "Corrigendum to Encephalopathy Associated With Neurochondrin Autoantibodies."
10/01/2019 - "Encephalopathy Associated With Neurochondrin Autoantibodies."

01/01/2022 - "Our case expands the spectrum of neurochondrin autoimmunity to disorders involving major cognitive disorder such as AD dementia. "
01/01/2022 - "Our report aims to enlarge its phenotypic spectrum to encompass major cognitive disorder with very late onset never before reported in conjunction with neurochondrin antibodies. "